US drug maker Merck & Co., Inc. (MSD outside North America) is known for its best-selling immuno-oncology agents and vaccines and delivered a high-flying performance in China last year, despite rising local competition.
China HPV Demand Shaping Merck But Competitors Catching Up
Local Nine-Valent Options In Wings
Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.
